Malvern Instruments has announced the purchase of the Archimedes particle characterization system from Affinity Biosensors after having had an exclusive distribution agreement outside of North America and a co-marketing agreement in North America for the past two years. The system, including the intellectual property associated with it, is now fully owned by Malvern.
The Archimedes system measures parameters including particle size, mass, and concentration in the 0.05µm to 5µm range, and the company cites the ability to measure individual protein aggregates as a particular benefit for biotherapeutics development.
Malvern Managing Director Paul Walker commented, “Affinity Biosensors’ Archimedes system has brought the technique of resonant mass measurement into our range, and its close fit within our biopharmaceutical offering has encouraged us to secure its place and future development within Malvern. As part of our analytical toolkit for the biopharmaceutical industry, Archimedes sits alongside Zetasizer and NanoSight Nanoparticle Tracking Analysis systems, delivering a range of complementary solutions for quantifying early aggregation in bioformulations.“
The company also said that it had completed the previously announced acquisition of GE Healthcare Life Sciences’ MicroCal business.
Read the Malvern press release.
